Answers are grounded in this paper and cite their sources.
Genetic mutations predispose the serine protease inhibitor α 1 -antitrypsin to misfolding and polymerisation within hepatocytes, causing liver disease and chronic obstructive pulmonary disease. This misfolding occurs via a transiently populated intermediate state, but our structural understanding of this process is limited by the instability of recombinant α 1 -antitrypsin variants in solution. Here we apply NMR spectroscopy to patient-derived samples of α 1 -antitrypsin at natural isotopic abundance to investigate the consequences of disease-causing mutations, and observe widespread chemical shift perturbations for methyl groups in Z AAT (E342K). By comparison with perturbations induced by binding of a small-molecule inhibitor of misfolding we conclude that they arise from rapid exchange between the native conformation and a well-populated intermediate state. The observation that this intermediate is stabilised by inhibitor binding suggests a paradoxical approach to the targeted treatment of protein misfolding disorders, wherein the stabilisation of disease-associated states provides selectivity while inhibiting further transitions along misfolding pathways.
No takes yet. Share an insight, caveat, or question.
Jagger et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: